Dr. Brent Guppy, William Donald Nash Brain Tumour Research Fellow

 Dr. Brent Guppy, Research Fellow

Project: Enhancing selumetinib-mediated killing of SHH medulloblastoma

Location: University of Manitoba


Read about the project

Medulloblastoma is the most common primary malignant childhood brain cancer and can be subdivided into at least 5 groups. One of these groups, named Sonic Hedgehog medulloblastoma, has a variable outcome in which some patients survive while others do not. Several efforts have been made to identify novel drugs to specifically treat Sonic Hedgehog medulloblastomas. Patients initially respond well to these drugs, however, the cancer cells can eventually develop drug resistance, which may ultimately lead to therapy failure and patient death. 

Researchers have identified “brain tumour stem cells” within Sonic Hedgehog tumours that appear to play an important role in drug resistance. Accordingly, considerable research efforts are dedicated to identifying and understanding these cell types, which are generally considered to be at the “root” of drug resistance within several cancer types including Sonic Hedgehog medulloblastoma. We recently discovered an important marker on the surface of Sonic Hedgehog medulloblastoma tumors that is associated with these types of “brain tumour stem cells”. We have discovered that cells bearing this marker can be specifically targeted and killed with a drug named selumetinib. Although our preliminary evidence shows selumetinib to be a promising new drug strategy to treat Sonic Hedgehog medulloblastomas, we wish to further increase the efficiency of selumetinib by combining it with additional cancer fighting drugs. Consequently, our study will test the combination of selumetinib with other known cancer fighting drugs with the goal of increasing survival and enhancing the quality of life for those children who survive long term. 

Read about what being awarded this Fellowship means to Brent

"Being awarded the William Donald Nash Brain Tumour Research Fellowship has accelerated my research goals of increasing the survival and improving the lives of pediatric brain tumour patients worldwide. 

Current treatment for medulloblastoma typically involves surgery, chemotherapy, and radiation, which target the cancer cells and healthy developing brain cells alike. Accordingly, medulloblastoma survivors often suffer from neurological, endocrinological, and social challenges as they mature. Therefore, rational biomarker classification for medulloblastoma subgroups is an essential step towards better patient stratification, better clinical trial design. Moreover, identification of novel molecularly targeted therapies would ultimately allow for current aggressive treatment strategies to be attenuated. Enhanced chemotherapeutic strategies such as the ones proposed in my study could limit the collateral damage to the developing nervous system and improve the quality of life for those who survive long term.       

Working closely with Dr. Werbowetski-Ogilvie and colleagues, we will identify an optimal selumetinib-based combinatorial drug therapy, characterize mechanisms of Sonic Hedgehog medulloblastoma drug resistance, and identify novel druggable targets that will be exploited by the next generation of chemotherapeutics designed to reduce the morbidity and mortality associated with medulloblastoma.

I would like to thank the Nash Family for continuing to support the Brain Tumour Foundation of Canada fellowships. It is through generous donations like yours that bring hope to those most in need."

Read more about William Donald Nash, the man who inspired and gave to launch this important research program.
Help build Canada's brain tumour research community by funding a Brain Tumour Research Fellowship. Contact us at 1-800-265-5106, ext. 229 or at sfelliott@braintumour.ca

<Back to Research Fellowships

For more information about brain tumour research funding and programs, please contact:

Susan Ruypers
Research Program Specialist
1-800-265-5106 ext 240


Share This

Featured Story

Hayden's Story: The eyes have it

Eyes might be the window to the soul, but in Hayden’s case, they were telling her Mom that something was seriously wrong with her baby. Hayden’s Mom, Candice, is forever grateful to the ER physician who spotted her brain tumour and the health care professional team who subsequently saved her eyesight. Candice is now advocating for every parent to look to the eyes.

Learn more


Tracey’s Story: Hope and Optimism

Headaches are like house guests. Some come and go. Others don’t want to leave; and become a real nuisance. Tracey’s headache lasted a...

Learn more

Andrew’s story of being tough

What do you see when you look in the mirror? When Andrew’s friend looked at him, he saw an immensely tough person and wanted to let...

Learn more

Upcoming Events

  • 15/Jan/2019: North Bay Support Group: Meets at St. Luke's Catholic Elementary School, 225 Milani Road, North Bay.... Learn more >
  • 16/Jan/2019: Windsor Support Group: Meets at the United Way, Unit A1, 300 Giles Blvd. East... Learn more >
  • 16/Jan/2019: Calgary Support Group: Meets at Wellspring Calgary, 1404 Home Road NW, Calgary, Alberta, T3B 1G7... Learn more >
  • 16/Jan/2019: Niagara Region Support Group: Meets at Wellspring Niagara, 3250 Schmon Parkway, Thorold, ON, L2V 4Y6... Learn more >
View All Events >
Thank you to the donors whose contributions make this website and all programs, services and research possible.

Copyright © 2019 Brain Tumour Foundation of Canada. Charitable Registration #BN118816339RR0001